Stimulation programs for pediatric drug research – do children really benefit? by Boots, Isabelle et al.
ORIGINAL PAPER
Stimulation programs for pediatric drug
research – do children really benefit?
Isabelle Boots & Rám N. Sukhai & Richard H. Klein &
Robert A. Holl & Jan M. Wit & Adam F. Cohen &
Jacobus Burggraaf
Received: 26 September 2006 /Accepted: 16 November 2006 / Published online: 17 January 2007
# Springer-Verlag 2007
Abstract Most drugs that are currently prescribed in
pediatrics have not been tested in children. Pediatric drug
studies are stimulated in the USA by the pediatric
exclusivity provision under the Food and Drug Adminis-
tration Modernization Act (FDAMA) that grants patent
extensions when pediatric labeling is provided. We inves-
tigated the effectiveness of these programs in stimulating
drug research in children, thereby increasing the evidence
for safe and effective drug use in the pediatric population.
All drugs granted pediatric exclusivity under the FDAMA
were analyzed by studying the relevant summaries of
medical and clinical pharmacology reviews of the pediatric
studies or, if these were unavailable, the labeling informa-
tion as provided by the manufacturer. A systematic search
of the literature was performed to identify drug utilization
patterns in children. From July 1998 to August 2006, 135
drug entities were granted pediatric exclusivity. Most
frequent drug groups were anti-depressants and mood
stabilizers, ACE inhibitors, lipid-lowering preparations,
HIV antivirals, and non-steroidal anti-inflammatory and
anti-rheumatic drugs. The distribution of the different drugs
closely matched the distribution of these drugs over the
adult market, and not the drug utilization by children.
Many drug studies in children have been performed
since the introduction of the FDAMA. However, children
infrequently use the drugs granted pediatric exclusivity. The
priorities for pediatric drug research should be set by the




ACE angiotensin converting enzyme
ATC anatomical therapeutical classification
EMEA European Medicines Agency
EU European Union
FDA Food and Drug Administration
FDAMA FoodandDrugAdministrationModernizationAct
ICH International Conference on Harmonization
ICU intensive care unit
SPC supplementary protection certificate
USA United States of America
PUMA Pediatric Use Marketing Authorization
Introduction
Most drugs prescribed in pediatrics have not been tested in
children. A recent review demonstrates that up to 80% of
prescriptions for children in hospital and in general practice
are either unlicensed (without a license for children) or used
off-label (outside the product license) [15]. Of commercial-
ly available drugs in Europe, only 35% are authorized for
use in children [4]. Although there are reasons why children
do not often participate in clinical trials, including ethical,
scientific and commercial considerations [2, 25], it is
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have not been studied properly.
In 1997, the Food and Drug Administration (FDA) and the
Congress introduced the Food and Drug Administration
Modernization Act (FDAMA), and this was followed by the
Best Pharmaceuticals for Children Act. Closely linked to this
legislation is the Pediatric Rule (1998), which requires the
industryto perform research in the pediatric population. In the
European Union (EU), final legislation on this topic has been
approved and will come into effect at the beginning of 2007.
In both continents, the measures taken to address the
problems broadly follow the same pattern. The first
incentive is aimed at new medicines and intended for
products covered by a patent or a supplementary protection
certificate (SPC). For these drugs, a 6-month extension of
market exclusivity is granted if a pediatric study is
performed. The second incentive has the objective of
increasing the knowledge on drugs that are no longer
patent protected. In order to obtain the data necessary to
establish safety, quality and efficacy specifically in chil-
dren, either funding for the studies (USA) or market
exclusivity (a so-called Pediatric Use Marketing Authori-
zation—PUMA) can be given. Central to the second
incentive is that experts are involved in determining for
which drugs the greatest medical need exists and in
ensuring that these drugs will be given priority. In the
USA, the FDA plays this central role, and in the EU, a
Pediatric Committee will be established within the
European Medicines Agency (EMEA) which will be given
a similar role.
The EU Commission apparently follows the approach in
the USA with regard to patent-protected drugs because,
according to the EU Commission, “the pediatric exclusivity
provision has been extremely successful in the USA in
stimulating the development of medicinal products for
pediatric use” [1].
At the brink of implementing new programs (EU) or
decisions on continuation of existing programs (USA), we
questioned what the influence of the pediatric exclusivity
regulation has been on pediatric drug development. We
evaluated the drugs that are granted pediatric exclusivity in
the USA by studying research that has been performed as a
consequence of the exclusivity provision, and by compar-
ing the drugs granted pediatric exclusivity with medicines
actually used by children.
Materials and methods
The drugs granted pediatric exclusivity since the introduction
of the FDAMA in July1998 until August2006were retrieved
from the FDA website [17]. All drugs were classified into
subgroups according to the Anatomical Therapeutical Clas-
sification (ATC) system of the European Pharmaceutical
Marketing Research Association. The data submitted to the
FDA that resulted in granting the exclusivity were examined.
For each drug, the publicly available summaries of medical
and clinical pharmacology reviews of the pediatric studies
were scrutinized. These summaries contain information on
the pediatric research performed to obtain pediatric exclu-
sivity. If these summaries were unavailable, the labeling
information of the drug with pediatric exclusivity was
studied to retrieve information about the pediatric studies
performed. Each drug label contains a pediatrics section
stating whether the drug is tested in children and, if so,
information on the performed studies is given [6, 17, 26].
Data were extracted about the type of study, number and age
of participants, whether long-term follow-up (defined as
>1 year with specific attention for long term effects on
growth and development) was undertaken and whether the
study led to a pediatric indication being included on the
label. Participants were divided into pediatric age categories
according to the International Conference on Harmonization
(ICH) guidelines: neonates (birth–27 days), infants (28 days–
23 months), children (2–11 years) and adolescents (12–
18 years).
To obtain data about drug use in children, recently
publishedsurveysofdrugprescribinginhospitalsandgeneral
practicewerereviewedbya systematicsearchofthe literature
on drugs used by children. Details on the literature search and
selectioncriteriaareprovidedinbox1.Druguseinadultswas
assessed by using the sales figures from public databases and
publications thereof [7, 8]. The data were categorized
according to the ATC system as mentioned above.
Literature search and selection strategy
Step 1: literature searches of the PubMed and Embase
bibliographic databases for papers published in English
between 1990 and July 2005 combining the following search
terms (keywords and appropriate medical subject headings):
– Child, preschool (or) child (or) infant (or) infant,
newborn (or) adolescent (or) pediatric (or) paediatric
(or) paediatrics.
– Pharmaceutical preparations (or) drugs, non-prescrip-
tion (or) drugs, generic (or) drug, therapy (or) pre-
scriptions, drug (or) medicine (or) medication.
– Drug utilization (or) pharmacoepidemiology (or) drug
utilization review.
Step 2: the references contained in articles identified in
step 1 were examined to identify further relevant studies.
Step 3: based on the titles and abstracts of the papers, we
next identified and then located full-text copies of 35
potentially relevant studies for closer examination.
850 Eur J Pediatr (2007) 166:849–855Step 4: selection of articles by two independent reviewers
(I.B., R.S.), using the following selection criteria:
– Study performed in the industrialized world, defined as
in Europe, North America, Australia and New Zealand.
– Study population of children from 0 to at least 14
years, to include all age groups (neonates, infants,
children and adolescents).
– Sufficient information in the paper about drug utilization
to classify 90% of the drugs in an ATC drug groups.
– Avoidance of selection bias by exclusion of voluntary
surveys.




According to the FDA, 135 drugs (130 active moieties)
were granted pediatric exclusivity from July 1998 to
August 2006. Most frequent drug groups were central
nervous system drugs (19%), such as anti-depressants and
psycholeptics, cardiovascular drugs (16%), mainly ACE
inhibitors and lipid-lowering preparations, systemic anti-
infectives (12%), among which largely HIV antivirals,
cytostatics (11%), and alimentary tract medication (12%),
among which proton pump inhibitors and oral antihyper-
glycemic medication (Table 1).
From 118 drugs (91%), information about studies
performed in children to obtain pediatric exclusivity could
be retrieved from the FDA summaries of medical and
clinical pharmacology reviews (n=61) of the pediatric
studies or the prescribing information as provided by the
manufacturer (n=57). No information could be found on 12
of the drug entities, mainly including over the counter
drugs. The product label of 13 drugs merely stated that
safety and/or efficacy in the pediatric population had not
been established. For the remaining 105 drugs, in total, 326
studies were performed for the approval of pediatric
exclusivity. At least 40,075 pediatric patients participated
in these 326 studies (the number of participants was not
noted for 27 of these studies). In the majority of the
Table 1 Active moieties granted pediatric exclusivity according to ATC group
Drug category Number of
drugs (% of total)
Most frequent drug classes Number
of drugs
Central nervous system 24 (19%) Anti-depressants 8




Cardiovascular system 21 (16%) ACE inhibitors, plain 6
HMG-CoA reductase inhibitors 5
Beta-blocking agents 4
Alimentary tract and metabolism 16 (12%) Drugs for peptic ulcer and gastro-oesophageal reflux disease 5
Oral blood glucose lowering drugs 4
Anti-infectives for systemic use 15 (12%) Direct acting antivirals 10
Antibacterials for systemic use 4
Antineoplastic and immunomodulating agents 14 (11%) Other antineoplastic agents 5
Antimetabolites 3
Alkylating agents 2
Musculo-skeletal system 7 (5%) Anti-inflammatory and anti-rheumatic products, non-steroids 6
Drugs affecting bone structure and mineralization 1
Respiratory system 10 (8%) Antihistamines for systemic use 4
Drugs for obstructive airway disease 3
Decongestants and other nasal preparations for topical use 2
Sensory organs 10 (8%) Antiglaucoma preparations and miotics 4
Decongestants and anti-allergics 3
Dermatologicals 6 (5%) Corticosteroids, potent (group 3) 3
Genito-urinary system and sex-hormones 3 (3%) Other urologicals, including antispasmodics 2
Blood and blood forming organs 2 (2%) Anti-thrombotic agents 1
Systemic hormonal preparations 1 (1%) Hypothalamic hormones 1
Parasitology 1 (1%) Anti-malarials 1
Total 130 (100%)
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Information on the age of participants was not provided for
54 of the 326 studies. Children participated in 224 of the
remaining 272 studies (82%), adolescents in 177 (65%),
infants were included in 105 (39%) of the trials, and
neonates in 38 trials (14%). Only 1 (0.4%) study included
preterm infants. The objective of most (62%) of the 326
studies was to determine the safety and efficacy of a drug.
Pharmacokinetics and/or pharmacodynamics were studied
in 147 (45%) trials, efficacy-only in 13 (4%) and safety-
only in 38 (12%). From the 299 studies in which
information about the number of participants was given,
on average 134 children participated per study. This varied
from 8 children in a safety and efficacy study of a HIV
antiviral in neonates, to 994 children participating in a
safety database of an antibiotic. Long-term (>1 year)
follow-up was either done or planned for 25 (21%) of the
118 drugs.
For 42% of the drugs granted pediatric exclusivity and
for which information was available (50 out of 118), the
information obtained from the pediatric studies led to an
approved pediatric indication.
The 130 active moieties granted pediatric exclusivity
were categorized according to the ATC system. The results
are shown in Table 1.
Drug utilization by children and adults
The search strategy retrieved nine papers addressing drug
utilization in children (Table 2). The data were summarized
by calculating a weighted average for each drug category
with weights proportional to the number of prescriptions
(Table 3). Drugs most often used by children are respiratory
drugs, anti-infectives for systemic use and dermatologicals.
The pattern of drug use in adults based on sales over the
last 12 months to May 2005 (Table 4) shows that drugs
used for central nervous system, cardiovascular, alimentary
tract and metabolism disorders make up over 50% of the
market.
Discussion
The introduction of the pediatric exclusivity laws in the
USA has led to pediatric drug trials for 135 drugs tested in
the past eight years. Over 300 studies were performed with
over 40,000 pediatric patients participating. Based on these
data, the FDA claims “the pediatric exclusivity provision
has done more to generate clinical studies and useful
prescribing information for the pediatric population than
any other regulatory or legislative process to date” [20].
The EU Commission and other policy makers see a rapid
adaptation of similar legislation in Europe essential to boost
pediatric drug research in the EU as soon as possible [1, 3,
19]. Although it is true that more pediatric studies have
been done, we question the content of the research.
A major discrepancy is apparent between the drug
prescription pattern in children and the drugs granted
pediatric exclusivity. The majority of drugs granted
pediatric exclusivity are rarely used by children, and drugs
that are frequently used by children are underrepresented in
the pediatric studies to obtain exclusivity. This difference is
not accounted for by the licensing status of the used drugs.
For instance, in general practice, 37% of the prescriptions
of respiratory drugs are still used in an unlicensed or off-
label manner [27]. This suggests that the pediatric studies
did not address the real needs in pediatric drug develop-
ment. Whilst the pediatric exclusivity scheme has stimulat-
ed pediatric research quantitatively, the nature of the
scheme has led to priorities for the type of research that
are largely driven by the adult market for medicines rather
than by the needs of the pediatric population. An important
built-in motive in the stimulation program for performing
pediatric studies is the financial benefit gained from the
Table 2 Characteristics of included studies on pediatric drug utilization






Niclasen [14] (1995) Pharmacy dispensing records in-and outpatients 1,704 0–14 5,876
Rokstad [21] (1997) Prescriptions of general practitioners
a 0–19 8,215
Thrane [28] (1999) Pharmacoepidemiological prescription database outpatients 48,091 0–15 154,189
Schirm
b [24] (2000) Pharmacy dispensing records outpatients 15,001 0–16 373,925
Lewis [12] (2001) Prescriptions pediatric outpatients 12,628 0–16 33,140
Pandolfini [16] (2002) Prescriptions general pediatric hospitals 1,325 0–14 4,265
Schirm [23] (2003) Pharmacy dispensing records outpatients 18,943 0–16 66,222
Ufer [30] (2003) Pharmacy dispensing records outpatients 357,784 0–16 644,817
Sanz [22] (2004) Prescriptions outpatients by GPs and pediatricians 12,264 0–14 27,486
a Not stated
b Not included in weighted average due to presentation of data in paper (percentage of children using a drug category).
852 Eur J Pediatr (2007) 166:849–855exclusivity provision. The drugs granted pediatric exclu-
sivity include 5 out of the “Top 10” prescription drugs with
the highest sales figures in North America in 2005:
atorvastatin (Lipitor), simvastatin (Zocor), omeprazole
(Nexium), lansoprazol (Prevacid), and sertraline (Zoloft).
Sales of these 5 drugs amounted to $24.1 billion US in
2005 [9]. Extension of the SPC on the basis of pediatric
exclusivity has also been granted to other adult best-selling
drugs, such as pravastatine, enalapril, metformin, amlodi-
pine, paroxetine, fluoxetine, and rofecoxib (currently
withdrawn). It is thus clear that the patent extension has
an enormous financial benefit for the pharmaceutical
companies, which easily outweighs the cost of the average
pediatric trial [1]. This is not only the case for best-selling
drugs but also for drugs with a smaller market share. A
Tufts University report indicates that an estimated $35
million US in undiscounted profits per drug can be earned
by obtaining pediatric exclusivity based on median 2004
sales for all pediatric exclusivity drugs after accounting for
costs and market protection extensions [29]. Although the
increased profit was intended by the legislator, we doubt if
the other intention, which aimed at providing data to reduce
the volume of drugs taken by children that are off-label or
unlicensed, has also been met.
Our approach to define essential drugs for children by
volume and by number of children that need a certain
medicine is incomplete, as indications and severity of the
conditions for which the drug is prescribed also play an
important role [10]. Secondly, the method employed in our
literature search may have introduced some bias toward
outpatient drug consumption, thus underestimating the use
of, for example, anesthetic or cardiovascular drugs. Clearly,
hypertension or lipid disorders occur in children, and
Table 4 Drug utilization patterns in adults, according to the drug
sales in North America over the period May 2004–May 2005
Drug category Adult prescriptions
Central nervous system 23%
Cardiovascular system 19%
Alimentary tract and metabolism 14%
Respiratory system 9%
General anti-infectives, systemic 8%
Musculo-skeletal system 6%
Genito-urinary system and sex-hormones 6%
Other 2%
Antineoplastic and immunomodulating agents 4%
Dermatologicals 3%
Blood and blood forming organs 3%
Sensory organs 2%
Total 100%
Table 3 Drug utilization
pattern in children Drug category % of
prescriptions
Frequent used drug classes
Respiratory system 30 % Drugs for obstructive airway disease
Nasal preparations
Cough and cold preparations
Antihistamines for systemic use
General anti-infectives, systemic 28% Antibacterials for systemic use
Dermatologicals 12% Antifungals for dermatological use
Emollients and protectives
Corticosteroids, dermatological preparations
Sensory organs 7% Ophtalmologicals
Otologicals
Central nervous system 4% Analgesics/ antipyretics
Psychostimulants, agents used for ADHD and
nootropics
Anti-epileptics
Hormones 3% Corticosteroids, for systemic use
Blood and blood forming organs 3% Vitamin K
Alimentary tract and metabolism 2% Drugs for peptic ulcer and gastro-oesophageal
reflux disease
Insulins and analogues
Musculo-skeletal system 2% Anti-inflammatory and anti-rheumatic
products, non-steroids
Genito-urinary system and sex-hormones 2% Hormonal contraceptives for systemic use
Cardiovascular system 1% Diuretics
Other <1%
Total 105% (exceeds 100% due to rounding)
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tant. However, these conditions are certainly not major
causes of morbidity, and subsequent drug use in children
and the research priorities lie elsewehere.
Furthermore, there are specific issues in pediatric clinical
pharmacology that have remained unaddressed by the
current product-related approach. First, the age distribution
of the children participating in the trials does not reflect the
actual medical needs. Drug use in children follows a
pattern, with a relatively high percentage of children using
a prescription drug in the first year of life [24] while the
proportion of off-label and unlicensed drug use is highest
(∼90%) in the vulnerable group of neonatal ICU patients
[5]. These data are not reflected in the participation in the
trials to obtain pediatric exclusivity, with neonates and
infants being included in, respectively, 14 and 39% of the
study groups. In fact, it is surprising to see that the majority
of applications included children of a wide age range,
thereby ignoring the delineation of age groups as defined in
the ICH guidelines. This is problematic, as in the pediatric
population significant age-related differences may exist in
the pharmacokinetics and the effects of drugs [11].
Secondly, the effects of drugs (that are intended for chronic
use) on development and maturation of children are largely
unknown, but this issue has hardly been addressed. Third,
off-label drugs are hardly or not studied. Only ten drugs in
this category are under consideration for study by pharma-
ceutical companies (FDA website). From these ten drugs,
six already have been refused by industry for studying, and
have been referred to the National Institutes of Health to
obtain the necessary information for rational use in
pediatric populations. These clinical trials are at the
moment awaiting funding [13, 18]. Surprisingly, in the
same Tufts study that reports on a profit of $35 million US
per drug granted exclusivity, it is also suggested that the
current incentives for studying non-patent protected drugs
are too low [29].
Finally, methodological research has remained under-
funded by this approach. Any expansion of research will
require specialized techniques that allow samples and data
to be obtained in children with minimal discomfort and
risk. For instance, most pharmacokinetic assays require an
amount of blood that is too large for the average neonate, so
highly sensitive assays need to be developed. Accurate
assessment of drug effects on neuro-development and
behavior also require further development, independently
of studies with particular compounds.
The recently approved EU guidelines contain differences
from the USA that may remedy some of the deficiencies
indicated. It contains a section for the stimulation of off-
patent drugs that can be granted a special label (PUMA),
and data protection if data necessary to establish safety,
quality and efficacy in children are submitted. The
‘Medicines Investigation for the Children of Europe’
program, funded by the EU, will be created to stimulate
research of off-patent drugs. The proposed establishment of
a Pediatric Committee, operating within the European
Medicines Agency, will guard study of significant drugs
for children and avoid unnecessary studies, provide free
advice to industry, and stimulate long-term pharmacovigi-
lance. It will also play a role in the implementation of the
requirement for industry to submit data they already hold
on use of their medicines in children. New drugs will not be
granted Marketing Authorisation unless the need for
pediatric research has been waived by the Pediatric
Committee, or deferral of initiation or completion of an
already approved Pediatric Investigation Plan has been
agreed to by this committee. In addition, an EU network of
investigators and trial centers will be formed [1]. Although
elements of this network are now beginning to form, their
funding is unclear and certainly not at the level provided to
the patent holders by a patent extension. Also, it is not
immediately clear why the EU measures will deliver, when
this was not achieved with the formation of Pediatric
Pharmacology Research Units and the oversight of research
priorities by the FDA in the USA.
In conclusion, the schemes implemented in the US
generated new knowledge and led to the rapid development
of an infrastructure to carry out pediatric drug trials.
Although these are certainly positive developments, we do
believe that the findings of this survey warrant additional
efforts to stimulate research on drugs used more frequently
by children, and generally applicable methodological re-
search, as at least the short-term effect of these initiatives
seems to have drawn the focus of industry-sponsored
research to the most profitable part of the market. The
funding of the research we propose should not be problem-
atic. The pediatric exclusivity schemes generate a flow of
public money to the sponsoring drug companies because
generic replacement and price reductions are postponed.
There is no particular reason why these public funds could
not be at least partly applied in an alternative manner.
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